Eton Pharmaceuticals, Inc. (NASDAQ:ETON) CEO Acquires $21,000.00 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETONGet Rating) CEO Sean Brynjelsen bought 10,000 shares of the firm’s stock in a transaction dated Thursday, September 22nd. The stock was bought at an average cost of $2.10 per share, with a total value of $21,000.00. Following the transaction, the chief executive officer now directly owns 1,040,000 shares of the company’s stock, valued at $2,184,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Eton Pharmaceuticals Price Performance

NASDAQ ETON traded down $0.16 on Friday, hitting $2.01. 999 shares of the stock traded hands, compared to its average volume of 41,206. The stock has a 50-day moving average of $2.50 and a 200 day moving average of $3.11. Eton Pharmaceuticals, Inc. has a twelve month low of $2.01 and a twelve month high of $6.72. The company has a current ratio of 5.19, a quick ratio of 5.05 and a debt-to-equity ratio of 0.45.

Eton Pharmaceuticals (NASDAQ:ETONGet Rating) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.09). Eton Pharmaceuticals had a negative net margin of 72.81% and a negative return on equity of 79.73%. The firm had revenue of $7.36 million for the quarter, compared to analyst estimates of $7.77 million. Equities research analysts expect that Eton Pharmaceuticals, Inc. will post -0.44 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Eton Pharmaceuticals in a research note on Friday, August 12th.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp grew its holdings in Eton Pharmaceuticals by 9.3% in the 1st quarter. State Street Corp now owns 91,603 shares of the company’s stock worth $399,000 after buying an additional 7,831 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Eton Pharmaceuticals during the 1st quarter worth $106,000. PDT Partners LLC bought a new stake in shares of Eton Pharmaceuticals during the 1st quarter worth $102,000. Goldman Sachs Group Inc. purchased a new stake in shares of Eton Pharmaceuticals in the first quarter valued at $77,000. Finally, Virtu Financial LLC purchased a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth about $67,000. 23.48% of the stock is currently owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

(Get Rating)

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Further Reading

Insider Buying and Selling by Quarter for Eton Pharmaceuticals (NASDAQ:ETON)

Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with's FREE daily email newsletter.